Mitochondrial organization and structure are compromised in fibroblasts from patients with Huntington’s disease

References

• Scheffler IE. Structure and Morphology. Integration into the Cell. Mitochondria: John Wiley & Sons, Inc; 2007:18–59.
   Google Scholar
• Zalman LS, Nikaido H, Kagawa Y. Mitochondrial outer membrane contains a protein producing nonspecific diffusion channels. J Biol Chem. 1980;255(5):1771–1774. doi:10.1016/S0021-9258(19)85942-2.
   PubMed Web of Science ®Google Scholar
• Koopman WJ, Visch HJ, Verkaart S, van den Heuvel LW, Smeitink JA, Willems PH. Mitochondrial network complexity and pathological decrease in complex I activity are tightly correlated in isolated human complex I deficiency. Am J Physiol Cell Physiol. 2005;289(4):C881–90. doi:10.1152/ajpcell.00104.2005.
   PubMed Web of Science ®Google Scholar
• Brantova O, Tesarova M, Hansikova H, Elleder M, Zeman J, Sladkova J. Ultrastructural changes of mitochondria in the cultivated skin fibroblasts of patients with point mutations in mitochondrial DNA. Ultrastruct Pathol. 2006;30(4):239–245. doi:10.1080/01913120600820112.
   PubMed Web of Science ®Google Scholar
• Zhu DP, Economou EP, Antonarakis SE, Maumenee IH. Mitochondrial DNA mutation and heteroplasmy in type I Leber hereditary optic neuropathy. Am J Med Genet. 1992;42(2):173–179. doi:10.1002/ajmg.1320420208.
   PubMed Web of Science ®Google Scholar
• DiMauro S, Bonilla E, Zeviani M, Nakagawa M, DeVivo DC. Mitochondrial myopathies. Ann Neurol. 1985;17(6):521–538. doi:10.1002/ana.410170602.
   PubMed Web of Science ®Google Scholar
• Lionaki E, Markaki M, Palikaras K, Tavernarakis N. Mitochondria, autophagy and age-associated neurodegenerative diseases: new insights into a complex interplay. Biochim Biophys Acta. 2015;1847(11):1412–1423. doi:10.1016/j.bbabio.2015.04.010.
   PubMed Web of Science ®Google Scholar
• Hedskog L, Zhang S, Ankarcrona M. Strategic role for mitochondria in Alzheimer’s disease and cancer. Antioxid Redox Signal. 2012;16(12):1476–1491. doi:10.1089/ars.2011.4259.
   PubMed Web of Science ®Google Scholar
• Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington’s disease and four dominant cerebellar ataxias. Nature. 1995;378(6555):403–406. doi:10.1038/378403a0.
   PubMed Web of Science ®Google Scholar
• MacDonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–983. doi:10.1016/0092-8674(93)90585-E.
   PubMed Web of Science ®Google Scholar
• Sharp AH, Loev SJ, Schilling G, et al. Widespread expression of Huntington’s disease gene (IT15) protein product. Neuron. 1995;14(5):1065–1074. doi:10.1016/0896-6273(95)90345-3.
   PubMed Web of Science ®Google Scholar
• Trushina E, Dyer RB, Badger JD 2nd, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol. 2004;24(18):8195–8209. doi:10.1128/MCB.24.18.8195-8209.2004.
   PubMed Web of Science ®Google Scholar
• Huang B, Wei W, Wang G, et al. Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. Neuron. 2015;85(6):1212–1226. doi:10.1016/j.neuron.2015.02.026.
   PubMed Web of Science ®Google Scholar
• Giacomello M, Hudec R, Lopreiato R. Huntington’s disease, calcium, and mitochondria. Biofactors. 2011;37(3):206–218. doi:10.1002/biof.162.
   PubMed Web of Science ®Google Scholar
• Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington’s disease is dependent on age and CAG repeat length. J Neurochem. 2001;78(4):694–703. doi:10.1046/j.1471-4159.2001.00482.x.
   PubMed Web of Science ®Google Scholar
• Nasir J, Floresco SB, O’Kusky JR, et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81(5):811–823. doi:10.1016/0092-8674(95)90542-1.
   PubMed Web of Science ®Google Scholar
• Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5(1):40. doi:10.1186/1750-1172-5-40.
   PubMed Web of Science ®Google Scholar
• Valles A, Evers MM, Stam A, et al. Widespread and sustained target engagement in Huntington’s disease minipigs upon intrastriatal microRNA-based gene therapy. Sci Transl Med. 2021;13(588):588. doi:10.1126/scitranslmed.abb8920.
   Web of Science ®Google Scholar
• Shapiro L. First 2 groups enrolled in phase 1/2 trial of gene therapy AMT-130.March 22 2022. Available from: https://huntingtonsdiseasenews.com/2022/03/22amt-130-trial-huntingtons-gene-therapy-fully-enrolled-first-2-groups/.
   Google Scholar
• Byun S, Lee M, Kim M. Gene therapy for Huntington’s disease: the final strategy for a cure? J Mov Disord. 2022;15(1):15–20. doi:10.14802/jmd.21006.
   PubMed Web of Science ®Google Scholar
• Gardner J. Roche stops giving Huntington’s disease drug in closely watched study.[cited 2021 Mar 23] Available from: www.biopharmadive.com/news/rochestop-dosing-huntington-tominersen-ionis/597171.
   Google Scholar
• Vonsattel JPG, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369–384. doi:10.1097/00005072-199805000-00001.
   PubMed Web of Science ®Google Scholar
• Squitieri F, Falleni A, Cannella M, et al. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm. 2010;117(1):77–83. doi:10.1007/s00702-009-0328-4.
   PubMed Web of Science ®Google Scholar
• Ciammola A, Sassone J, Sciacco M, et al. Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington’s disease. Mov Disord. 2011;26(1):130–137. doi:10.1002/mds.23258.
   PubMed Web of Science ®Google Scholar
• Milakovic T, Johnson GV. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem. 2005;280(35):30773–30782. doi:10.1074/jbc.M504749200.
   PubMed Web of Science ®Google Scholar
• Guidetti P, Charles V, Chen EY, et al. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol. 2001;169(2):340–350. doi:10.1006/exnr.2000.7626.
   PubMed Web of Science ®Google Scholar
• Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington’s disease. Brain Pathol. 1999;9(1):147–163. doi:10.1111/j.1750-3639.1999.tb00216.x.
   PubMed Web of Science ®Google Scholar
• Jiang R, Diaz-Castro B, Looger LL, Khakh BS. Dysfunctional calcium and glutamate signaling in striatal astrocytes from huntington’s disease model mice. J Neurosci. 2016;36(12):3453–3470. doi:10.1523/JNEUROSCI.3693-15.2016.
   PubMed Web of Science ®Google Scholar
• Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol. 1983;13(1):72–78. doi:10.1002/ana.410130116.
   PubMed Web of Science ®Google Scholar
• Rodinova M, Krizova J, Stufkova H, et al. Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington’s disease. Dis Model Mech. 2019;12:7.
   Web of Science ®Google Scholar
• Mielcarek M. Huntington’s disease is a multi-system disorder. Rare Diseases. 2015;3(1):e1058464.doi:10.1080/21675511.2015.1058464.
   PubMed Web of Science ®Google Scholar
• Macakova M, Bohuslavova B, Vochozkova P, et al. Mutated huntingtin causes testicular pathology in transgenic minipig boars. Neurodegener Dis. 2016;16(3–4):245–259. doi:10.1159/000443665.
   PubMed Web of Science ®Google Scholar
• Gehrig SM, Petersen JA, Frese S, et al. Skeletal muscle characteristics and mitochondrial function in Huntington’s disease patients. Mov Disord. 2017;32(8):1258–1259. doi:10.1002/mds.27031.
   PubMed Web of Science ®Google Scholar
• Cankar K, Melik Z, Kobal J, Starc V. Evidence of cardiac electrical remodeling in patients with Huntington disease. Brain Behav. 2018;8(8):e01077–e. doi:10.1002/brb3.1077.
   PubMed Web of Science ®Google Scholar
• Askeland G, Dosoudilova Z, Rodinova M, et al. Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington’s disease patients. Sci Rep. 2018;8(1):9817. doi:10.1038/s41598-018-27985-y.
   PubMed Web of Science ®Google Scholar
• Kosinski CM, Schlangen C, Gellerich FN, et al. Myopathy as a first symptom of Huntington’s disease in a Marathon runner. Movement Disorders. 2007;22(11):1637–1640. doi:10.1002/mds.21550.
   PubMed Web of Science ®Google Scholar
• Gardiner SL, Milanese C, Boogaard MW, et al. Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset. Neurol Genet. 2018;4(5):e275–e. doi:10.1212/NXG.0000000000000275.
   PubMed Web of Science ®Google Scholar
• Jędrak P, Mozolewski P, Węgrzyn G, Więckowski MR. Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington’s disease patients. Metab Brain Dis. 2018;33(6):2005–2017. doi:10.1007/s11011-018-0308-1.
   PubMed Web of Science ®Google Scholar
• Costa V, Giacomello M, Hudec R, et al. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli. EMBO Mol Med. 2010;2(12):490–503. doi:10.1002/emmm.201000102.
   PubMed Web of Science ®Google Scholar
• Olichon A, Baricault L, Gas N, et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem. 2003;278(10):7743–7746. doi:10.1074/jbc.C200677200.
   PubMed Web of Science ®Google Scholar
• Park JY, Jang SY, Shin YK, et al. Mitochondrial swelling and microtubule depolymerization are associated with energy depletion in axon degeneration. Neuroscience. 2013;238:258–269. doi:10.1016/j.neuroscience.2013.02.033.
   PubMed Web of Science ®Google Scholar
• Ranftler C, Meisslitzer-Ruppitsch C, Neumüller J, Ellinger A, Pavelka M. Golgi apparatus dis- and reorganizations studied with the aid of 2-deoxy-D-glucose and visualized by 3D-electron tomography. Histochem Cell Biol. 2017;147(4):415–438. doi:10.1007/s00418-016-1515-7.
   PubMed Web of Science ®Google Scholar
• Sladkova J, Spacilova J, Capek M, et al. Analysis of mitochondrial network morphology in cultured myoblasts from patients with mitochondrial disorders. Ultrastruct Pathol. 2015;39(5):340–350. doi:10.3109/01913123.2015.1054013.
   PubMed Web of Science ®Google Scholar
• Kuznetsov AV, Veksler V, Gellerich FN, Saks V, Margreiter R, Kunz WS. Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. Nat Protoc. 2008;3(6):965–976. doi:10.1038/nprot.2008.61.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193(1):265–275. doi:10.1016/S0021-9258(19)52451-6.
   PubMed Web of Science ®Google Scholar
• Janssen AJ, Trijbels FJ, Sengers RC, et al. Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology. Clin Chem. 2006;52(5):860–871. doi:10.1373/clinchem.2005.062414.
   PubMed Web of Science ®Google Scholar
• Magner M, Vinsova K, Tesarova M, et al. Two patients with clinically distinct manifestation of pyruvate dehydrogenase deficiency due to mutations in PDHA1 gene. Prague Medical Report. 2011;112(1):18–28.
   PubMedGoogle Scholar
• Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta. 1994;228(1):35–51. doi:10.1016/0009-8981(94)90055-8.
   PubMed Web of Science ®Google Scholar
• Marques Sousa C, Humbert S. Huntingtin: here, there, everywhere! Journal of Huntington’s Disease. 2013;2(4):395–403. doi:10.3233/JHD-130082.
   PubMedGoogle Scholar
• Shirendeb U, Reddy AP, Manczak M, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum Mol Genet. 2011;20(7):1438–1455. doi:10.1093/hmg/ddr024.
   PubMed Web of Science ®Google Scholar
• Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem. 2012;120(3):419–429. doi:10.1111/j.1471-4159.2011.07581.x.
   PubMed Web of Science ®Google Scholar
• Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell. 2007;130(3):548–562. doi:10.1016/j.cell.2007.06.026.
   PubMed Web of Science ®Google Scholar
• Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet. 2009;18(R2):R169–76. doi:10.1093/hmg/ddp326.
   PubMed Web of Science ®Google Scholar
• Jin YN, Yu YV, Gundemir S, et al. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One. 2013;8(3):1.
   Web of Science ®Google Scholar
• Hering T, Kojer K, Birth N, Hallitsch J, Taanman J-W, Orth M. Mitochondrial cristae remodelling is associated with disrupted OPA1 oligomerisation in the Huntington’s disease R6/2 fragment model. Exp Neurol. 2017;288:167–175. doi:10.1016/j.expneurol.2016.10.017.
   PubMed Web of Science ®Google Scholar
• Jodeiri Farshbaf M, Ghaedi GK. Huntington’s disease and mitochondria. Neurotox Res. 2017;32(3):518–529. doi:10.1007/s12640-017-9766-1.
   PubMed Web of Science ®Google Scholar
• Cogliati S, Enriquez JA, Scorrano SL. Mitochondrial cristae: where beauty meets functionality. Trends Biochem Sci. 2016;41(3):261–273. doi:10.1016/j.tibs.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Bravo-Sagua R, Torrealba N, Paredes F, et al. Organelle communication: signaling crossroads between homeostasis and disease. Int J Biochem Cell Biol. 2014;50:55–59. doi:10.1016/j.biocel.2014.01.019.
   PubMed Web of Science ®Google Scholar
• Villeneuve J, Scarpa M, Ortega-Bellido M, Malhotra V. MEK1 inactivates Myt1 to regulate golgi membrane fragmentation and mitotic entry in mammalian cells. EMBO J. 2012;32(1):72–85. doi:10.1038/emboj.2012.329.
   PubMed Web of Science ®Google Scholar
• Fan J, Hu Z, Zeng L, et al. Golgi apparatus and neurodegenerative diseases. International Journal of Developmental Neuroscience. 2008;26(6):523–534. doi:10.1016/j.ijdevneu.2008.05.006.
   PubMed Web of Science ®Google Scholar
• Brandstaetter H, Kruppa AJ, Buss F. Huntingtin is required for ER-to-Golgi transport and for secretory vesicle fusion at the plasma membrane. Dis Model Mech. 2014;7(12):1335–1340. doi:10.1242/dmm.017368.
   PubMed Web of Science ®Google Scholar
• Yue Y, Qian Q, Gim G, Acyl-CoA-Binding Domain-Containing LI. 1School of Life Science and Technology, ShanghaiTech University, Pudong, Shanghai 201210, China; [email protected] (X.Y.); [email protected] (Y.Q.). Int J Mol Sci. 2019;20(8):2028. doi:10.3390/ijms20082028.
   PubMed Web of Science ®Google Scholar
• Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science (New York, NY). 2009;324(5932):1327–1330. doi:10.1126/science.1172871.
   Google Scholar
• Pandey M, Varghese M, Sindhu KM, et al. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington’s disease. J Neurochem. 2008;104(2):420–434.
   PubMed Web of Science ®Google Scholar
• Arenas J, Campos Y, Ribacoba R, et al. Complex I Defect in muscle from patients with Huntington’s disease. Ann Neurol. 1998;43(3):397–400. doi:10.1002/ana.410430321.
   PubMed Web of Science ®Google Scholar
• Kojer K, Hering T, Bazenet C, et al. Huntingtin aggregates and mitochondrial pathology in skeletal muscle but not heart of late-stage R6/2 mice. Journal of Huntington’s Disease. 2019;8(2):145–159. doi:10.3233/JHD-180324.
   PubMed Web of Science ®Google Scholar
• Benchoua A, Trioulier Y, Zala D, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell. 2006;17(4):1652–1663. doi:10.1091/mbc.e05-07-0607.
   PubMed Web of Science ®Google Scholar
• Browne SE, Bowling AC, Macgarvey U, Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41(5):646–653. doi:10.1002/ana.410410514.
   PubMed Web of Science ®Google Scholar
• Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol. 1996;39(3):385–389. doi:10.1002/ana.410390317.
   PubMed Web of Science ®Google Scholar
• Damiano M, Diguet E, Malgorn C, et al. A role of mitochondrial complex II defects in genetic models of Huntington’s disease expressing N-terminal fragments of mutant huntingtin. Hum Mol Genet. 2013;22(19):3869–3882. doi:10.1093/hmg/ddt242.
   PubMed Web of Science ®Google Scholar
• Naseri NN, Xu H, Bonica J, et al. Abnormalities in the tricarboxylic acid cycle in Huntington disease and in a Huntington disease mouse model. J Neuropathol Exp Neurol. 2015;74(6):527–537. doi:10.1097/NEN.0000000000000197.
   PubMed Web of Science ®Google Scholar
• Schiff L, Migliori B, Chen Y, et al. Integrating deep learning and unbiased automated high-content screening to identify complex disease signatures in human fibroblasts. Nat Commun. 2022;13(1):1590. doi:10.1038/s41467-022-28423-4.
   PubMed Web of Science ®Google Scholar
• Sonsky I, Vodicka P, Vodickova Kepkova K, Hansikova H. Mitophagy in Huntington’s disease. Neurochem Int. 2021;149:105147. doi:10.1016/j.neuint.2021.105147.
   PubMed Web of Science ®Google Scholar
• Traa A, Machiela E, Rudich PD, Soo SK, Senchuk MM, Van Raamsdonk JM. Identification of novel therapeutic targets for polyglutamine diseases that target mitochondrial fragmentation. Int J Mol Sci. 2021;22(24):24. doi:10.3390/ijms222413447.
   Web of Science ®Google Scholar